316 related articles for article (PubMed ID: 28465444)
21. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.
Kawai M; Nakashima A; Kamada S; Kikkawa U
J Biomed Sci; 2015 Jul; 22(1):48. PubMed ID: 26141684
[TBL] [Abstract][Full Text] [Related]
22. LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Li M; Viswanadhapalli S; Santhamma B; Pratap UP; Luo Y; Liu J; Altwegg KA; Tang W; Liu Z; Li X; Ebrahimi B; Yan H; Zou Y; Konda S; Sareddy GR; Xu Z; Chen Y; Rao MK; Brenner AJ; Kaklamani VG; Tekmal RR; Ahmed G; Raj GV; Nickisch KJ; Nair HB; Vadlamudi RK
Commun Biol; 2021 Oct; 4(1):1235. PubMed ID: 34716410
[TBL] [Abstract][Full Text] [Related]
23. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
Ludwik KA; Campbell JP; Li M; Li Y; Sandusky ZM; Pasic L; Sowder ME; Brenin DR; Pietenpol JA; O'Doherty GA; Lannigan DA
Mol Cancer Ther; 2016 Nov; 15(11):2598-2608. PubMed ID: 27528706
[TBL] [Abstract][Full Text] [Related]
24. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
[TBL] [Abstract][Full Text] [Related]
25. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Cheung A; Opzoomer J; Ilieva KM; Gazinska P; Hoffmann RM; Mirza H; Marlow R; Francesch-Domenech E; Fittall M; Dominguez Rodriguez D; Clifford A; Badder L; Patel N; Mele S; Pellizzari G; Bax HJ; Crescioli S; Petranyi G; Larcombe-Young D; Josephs DH; Canevari S; Figini M; Pinder S; Nestle FO; Gillett C; Spicer JF; Grigoriadis A; Tutt ANJ; Karagiannis SN
Clin Cancer Res; 2018 Oct; 24(20):5098-5111. PubMed ID: 30068707
[No Abstract] [Full Text] [Related]
26. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells.
Kabir S; Cidado J; Andersen C; Dick C; Lin PC; Mitros T; Ma H; Baik SH; Belmonte MA; Drew L; Corn JE
Elife; 2019 Jul; 8():. PubMed ID: 31294695
[TBL] [Abstract][Full Text] [Related]
27. The Role of Apoptotic Genes and Protein-Protein Interactions in Triple-negative Breast Cancer.
Adinew GM; Messeha S; Taka E; Ahmed SA; Soliman KFA
Cancer Genomics Proteomics; 2023; 20(3):247-272. PubMed ID: 37093683
[TBL] [Abstract][Full Text] [Related]
28. Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells.
Boedicker C; Hussong M; Grimm C; Dolgikh N; Meister MT; Enßle JC; Wanior M; Knapp S; Schweiger MR; Fulda S
Oncogene; 2020 May; 39(19):3837-3852. PubMed ID: 32161312
[TBL] [Abstract][Full Text] [Related]
29. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract][Full Text] [Related]
30. ATF3 Repression of BCL-X
Chüeh AC; Tse JWT; Dickinson M; Ioannidis P; Jenkins L; Togel L; Tan B; Luk I; Davalos-Salas M; Nightingale R; Thompson MR; Williams BRG; Lessene G; Lee EF; Fairlie WD; Dhillon AS; Mariadason JM
Clin Cancer Res; 2017 Sep; 23(18):5573-5584. PubMed ID: 28611196
[No Abstract] [Full Text] [Related]
31. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Zhang K; Liu Z; Yao Y; Qiu Y; Li F; Chen D; Hamilton DJ; Li Z; Jiang S
J Med Chem; 2021 Apr; 64(7):4020-4033. PubMed ID: 33745280
[TBL] [Abstract][Full Text] [Related]
32. 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck B; Bland P; Mavrommati I; Muirhead G; Cottom H; Wai PT; Maguire SL; Barker HE; Morrison E; Kriplani D; Yu L; Gibson A; Falgari G; Brennan K; Farnie G; Buus R; Marlow R; Novo D; Knight E; Guppy N; Kolarevic D; Susnjar S; Milijic NM; Naidoo K; Gazinska P; Roxanis I; Pancholi S; Martin LA; Holgersen EM; Cheang MCU; Noor F; Postel-Vinay S; Quinn G; McDade S; Krasny L; Huang P; Daley F; Wallberg F; Choudhary JS; Haider S; Tutt AN; Natrajan R
Cancer Res; 2021 Feb; 81(4):847-859. PubMed ID: 33509944
[TBL] [Abstract][Full Text] [Related]
33. Bcl-xL inhibition radiosensitizes
Pesch AM; Chandler BC; Michmerhuizen AR; Carter HM; Hirsh NH; Wilder-Romans K; Liu M; Ward T; Ritter CL; Nino CA; Jungles KM; Pierce LJ; Rae JM; Speers CW
Cancer Res Commun; 2022 Jul; 2(7):679-693. PubMed ID: 36381235
[TBL] [Abstract][Full Text] [Related]
34. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
[TBL] [Abstract][Full Text] [Related]
35. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
[TBL] [Abstract][Full Text] [Related]
36. Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.
Johnstone CN; Pattison AD; Gorringe KL; Harrison PF; Powell DR; Lock P; Baloyan D; Ernst M; Stewart AG; Beilharz TH; Anderson RL
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29720474
[TBL] [Abstract][Full Text] [Related]
37. Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
Kalin JH; Eroglu A; Liu H; Holtzclaw WD; Leigh I; Proby CM; Fahey JW; Cole PA; Dinkova-Kostova AT
PLoS One; 2019; 14(3):e0213095. PubMed ID: 30865688
[TBL] [Abstract][Full Text] [Related]
38. Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
Liao C; Glodowski CR; Fan C; Liu J; Mott KR; Kaushik A; Vu H; Locasale JW; McBrayer SK; DeBerardinis RJ; Perou CM; Zhang Q
Cancer Res; 2022 Feb; 82(4):665-680. PubMed ID: 34911787
[TBL] [Abstract][Full Text] [Related]
39. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
[TBL] [Abstract][Full Text] [Related]
40. MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
Zheng SM; Feng YC; Zhu Q; Li RQ; Yan QQ; Teng L; Yue YM; Han MM; Ye K; Zhang SN; Qi TF; Tang CX; Zhao XH; Zhang YY; Xu L; Xu R; Xing J; Baker M; Liu T; Thorne RF; Jin L; Preiss T; Zhang XD; Cang S; Gao JN
Cancer Res; 2024 May; 84(9):1460-1474. PubMed ID: 38593213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]